Names | |
---|---|
IUPAC name
18,21-Dihydroxypregn-4-ene-3,20-dione
| |
Systematic IUPAC name
(1S,3aS,3bR,9aR,9bS,11aR)-1-(Hydroxyacetyl)-11a-(hydroxymethyl)-9a-methyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-one | |
Other names
18,21-dihydroxy-4-pregnene-3,20-dione
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
EC Number |
|
MeSH | 18-hydroxydeoxycorticosterone |
PubChem
CID
|
|
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H30O4 | |
Molar mass | 346.5 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
18-Hydroxy-11-deoxycorticosterone (also known as 18-OH-DOC, 18,21-dihydroxyprogesterone, and 18,21-dihydroxypregn-4-ene-3,20-dione) is an endogenous steroid and a mineralocorticoid. It is a hydroxylated metabolite of 11-deoxycorticosterone. [1]
In rats, conversion of 11-deoxycorticosterone into 18-OH-DOC is catalyzed by the CYP11B3 enzyme. [2]
In humans, 18-OH-DOC is a weak mineralocorticoid. [3] It may be increased in 17α-hydroxylase ( CYP17A1) deficiency, [4] in aldosterone synthase ( CYP11B2) deficiency, [5] in primary aldosteronism, and may also indicate a histologic variant of the aldosteronoma. [4] Excessive secretion of 18-OH-DOC can cause mineralocorticoid excess syndrome, although these cases are very rare. [6]
Names | |
---|---|
IUPAC name
18,21-Dihydroxypregn-4-ene-3,20-dione
| |
Systematic IUPAC name
(1S,3aS,3bR,9aR,9bS,11aR)-1-(Hydroxyacetyl)-11a-(hydroxymethyl)-9a-methyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-one | |
Other names
18,21-dihydroxy-4-pregnene-3,20-dione
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
EC Number |
|
MeSH | 18-hydroxydeoxycorticosterone |
PubChem
CID
|
|
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H30O4 | |
Molar mass | 346.5 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
18-Hydroxy-11-deoxycorticosterone (also known as 18-OH-DOC, 18,21-dihydroxyprogesterone, and 18,21-dihydroxypregn-4-ene-3,20-dione) is an endogenous steroid and a mineralocorticoid. It is a hydroxylated metabolite of 11-deoxycorticosterone. [1]
In rats, conversion of 11-deoxycorticosterone into 18-OH-DOC is catalyzed by the CYP11B3 enzyme. [2]
In humans, 18-OH-DOC is a weak mineralocorticoid. [3] It may be increased in 17α-hydroxylase ( CYP17A1) deficiency, [4] in aldosterone synthase ( CYP11B2) deficiency, [5] in primary aldosteronism, and may also indicate a histologic variant of the aldosteronoma. [4] Excessive secretion of 18-OH-DOC can cause mineralocorticoid excess syndrome, although these cases are very rare. [6]